1 option
Clinical review report : indication : moderate-to-severe atopic dermatitis (AD). Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) / CADTH Canadian Drug Expert Committee.
- Format:
- Book
- Author/Creator:
- CADTH Canadian Drug Expert Committee, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Outcome assessment (Medical care)--Methodology.
- Physical Description:
- 1 online resource
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that Dupilumab not be reimbursed for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.